23 CAR § 151-103 – United States Food and Drug Administration approval and reporting

(a) Upon approval by the United States Food and Drug Administration of the use of intravenous immunoglobulin to treat individuals diagnosed with pediatric acute-onset neuropsychiatric syndrome or pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, or both, the Insurance Commissioner, with consultation and upon approval of the Arkansas State Medical Board and the Arkansas State Board of Pharmacy, will adopt by rule a written statewide protocol that provides clarification that the consultation required under 23 CAR § 151-102(b) and the patient-specific treatment plan required under 23 CAR § 151-102(a) are no longer required for coverage under a health benefit plan.
(b) A primary care physician who prescribes intravenous immunoglobulin to treat individuals diagnosed with pediatric acute-onset neuropsychiatric syndrome or pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, or both, shall report the data to the Childhood Postinfectious Autoimmune Encephalopathy Center of Excellence.